Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on September 6, 2018, reporting events occurring between August 31, 2018, and September 7, 2018. The filing details a new debt financing arrangement and the conversion of existing indebtedness into equity.
Key Financial Metrics and Transactions
- New Debt Financing: The Company issued a promissory note to Tangiers Global, LLC with a principal amount of $350,000. Net proceeds were $322,000, with $28,000 retained as an original issue discount for due diligence and legal expenses.
- Debt Terms: The note carries a guaranteed interest rate of 6% and matures on March 31, 2019. It is convertible at the lender's option into common stock at $2.15 per share.
- Debt-for-Equity Exchange: Between September 3 and September 7, 2018, the Company issued 308,206 shares of common stock to settle outstanding indebtedness totaling $292,095 (inclusive of accrued interest).
- Liquidity and Margins: The filing text does not provide clear values for revenue, profit, cash flow, or operating margins.
Material Changes
The primary material change is the increase in debt obligations via the Tangiers Note and the simultaneous reduction of other liabilities through the issuance of equity. The conversion price of $2.15 per share for the new note establishes a specific valuation metric for potential future dilution.
Outlook, Risks, and Contingencies
- Unregistered Sales: The equity issuances were conducted under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, relying on exemptions for transactions not involving a public offering and exchanges with existing security holders.
- Investor Status: Management reasonably believes all investors in these transactions are accredited investors.
- Future Obligations: The Company faces a repayment obligation of $350,000 plus 6% interest by March 31, 2019, unless converted by the lender.
Key Facts for Investor Verification
- Verify the Company's ability to repay the $350,000 Tangiers Note by March 31, 2019, or the impact of its conversion on existing shareholders.
- Confirm the total number of outstanding shares following the issuance of 308,206 shares for debt settlement.
- Review the full text of the Tangiers Note (Exhibit 10.1) for specific adjustment mechanisms regarding the $2.15 conversion price.
- Assess the Company's overall liquidity position given the reliance on debt financing and debt-for-equity swaps rather than revenue generation.